Clinical trials

  • ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES AND STROMAL CELLS for Heart failure | Heart failure with reduced ejection fraction (HFrEF)
  • N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3-NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE for Mantle cell lymphoma (relapsed or refractory)
  • ADAGRASIB for Non-small cell lung cancer | KRAS G12C-mutated non-small cell lung cancer
  • CEREBROLYSIN CONCENTRATE for Traumatic brain injury
  • GOLCADOMIDE for Follicular B-cell non-Hodgkin's lymphoma | Primary central nervous system lymphoma | Marginal zone lymphoma | Diffuse large B-cell lymphoma | Mantle cell lymphoma
  • VX-264 for Type 1 diabetes mellitus
  • AD-O51.4 for Advanced solid tumour | Solid tumour
  • Hydroxychloroquine sulfate for Recurrent pregnancy loss
  • ZILOVERTAMAB VEDOTIN for Diffuse large B-cell lymphoma
  • Enzalutamide for Metastatic prostate cancer
  • FARICIMAB for Polypoidal choroidal vasculopathy
  • Pioglitazone for Chronic myeloid leukemia (chronic phase)